[go: up one dir, main page]

TW200515910A - Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer - Google Patents

Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer

Info

Publication number
TW200515910A
TW200515910A TW093122704A TW93122704A TW200515910A TW 200515910 A TW200515910 A TW 200515910A TW 093122704 A TW093122704 A TW 093122704A TW 93122704 A TW93122704 A TW 93122704A TW 200515910 A TW200515910 A TW 200515910A
Authority
TW
Taiwan
Prior art keywords
inhibitor
cancer
treatment
combination
growth factor
Prior art date
Application number
TW093122704A
Other languages
English (en)
Inventor
Lee Martin Greenberger
Carolyn Mary Discafani-Marro
Philip Frost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200515910A publication Critical patent/TW200515910A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093122704A 2003-08-01 2004-07-29 Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer TW200515910A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01

Publications (1)

Publication Number Publication Date
TW200515910A true TW200515910A (en) 2005-05-16

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093122704A TW200515910A (en) 2003-08-01 2004-07-29 Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer

Country Status (19)

Country Link
US (1) US20050026933A1 (zh)
EP (1) EP1648516A2 (zh)
JP (1) JP2007501238A (zh)
KR (1) KR20060054412A (zh)
CN (1) CN1832757A (zh)
AR (1) AR045179A1 (zh)
AU (1) AU2004266572A1 (zh)
BR (1) BRPI0413255A (zh)
CA (1) CA2533126A1 (zh)
CO (1) CO5640151A2 (zh)
CR (1) CR8181A (zh)
EC (1) ECSP066341A (zh)
IL (1) IL173081A0 (zh)
MX (1) MXPA06001110A (zh)
NO (1) NO20060398L (zh)
RU (1) RU2006106267A (zh)
TW (1) TW200515910A (zh)
WO (1) WO2005018677A2 (zh)
ZA (1) ZA200600915B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622621B2 (en) * 2002-03-29 2009-11-24 Exxonmobil Chemical Patents Inc. Preparation of alkylaromatic hydrocarbons and alkylaryl sulfonates
CA2479466A1 (en) * 2002-03-29 2003-10-09 Exxonmobil Chemical Patents Inc. Oligomerization of olefins
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2005117915A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with oxaliplatin and an egfr-inhibitor
JP2008501654A (ja) 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー シスプラチンとｅｇｆｒ阻害剤を用いた治療
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP2594631A1 (en) 2005-04-05 2013-05-22 Cellpoint Diagnostics Devices and method for detecting circulating tumor cells and other particles
MX2007012662A (es) * 2005-04-14 2008-04-04 Wyeth Corp Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib.
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20080292729A1 (en) * 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
TW200803892A (en) 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) * 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
CA2663571A1 (en) * 2006-09-13 2008-03-20 Nuvelo, Inc. Methods for treating cancer
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
MY156789A (en) * 2008-09-05 2016-03-31 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
RU2012114902A (ru) 2009-09-16 2013-10-27 Авила Терапьютикс, Инк. Конъюгаты и ингибиторы протеинкиназы
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
HUE050761T2 (hu) 2014-01-01 2021-01-28 Medivation Tech Llc Vegyületek és alkalmazási eljárások
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04004969A (es) * 2001-11-27 2004-08-11 Wyeth Corp 3-cianoquinolinas como inhibidores del receptor del factor de crecimiento epidermico y her2 cinasas.

Also Published As

Publication number Publication date
CN1832757A (zh) 2006-09-13
ECSP066341A (es) 2006-08-30
WO2005018677A2 (en) 2005-03-03
AU2004266572A1 (en) 2005-03-03
BRPI0413255A (pt) 2006-10-03
MXPA06001110A (es) 2006-04-11
CR8181A (es) 2006-07-14
AR045179A1 (es) 2005-10-19
RU2006106267A (ru) 2006-07-27
CA2533126A1 (en) 2005-03-03
KR20060054412A (ko) 2006-05-22
WO2005018677A3 (en) 2006-05-26
CO5640151A2 (es) 2006-05-31
IL173081A0 (en) 2006-06-11
NO20060398L (no) 2006-02-28
EP1648516A2 (en) 2006-04-26
ZA200600915B (en) 2007-12-27
US20050026933A1 (en) 2005-02-03
JP2007501238A (ja) 2007-01-25

Similar Documents

Publication Publication Date Title
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
SG148202A1 (en) Quinazolinone compounds as anticancer agents
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
PT2100614E (pt) Antagonistas de receptor para tratamento de cancro ósseo metastático
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
SG164368A1 (en) Treatment of cancer
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
ZA200700057B (en) 2, 4, 6-Trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
UA90467C2 (ru) Применение пептидных соединений для лечения боли при болезненой диабетической невропатии
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
TW200718421A (en) Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
WO2008039525A3 (en) Cadherin antagonists in combination with anticancer agents for use in cancer treatment
WO2008036254A3 (en) Autophagic compounds and tyrosine kinase inhibitors for treating cancer
WO2006124689A3 (en) Combination therapy
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer